Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | dipeptidyl-peptidase 4 | Starlite/ChEMBL | References |
Plasmodium falciparum | beta-ketoacyl-ACP synthase III | Curated by TDR Targets | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | Dipeptidyl-peptidase 8-like, putative | 0.007 | 0.013 | 0.5 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.0383 | 0.2587 | 0.5 |
Echinococcus granulosus | dipeptidyl aminopeptidaseprotein | 0.0209 | 0.1221 | 0.1105 |
Toxoplasma gondii | dipeptidyl peptidase iv (dpp iv) n-terminal region domain-containing protein | 0.007 | 0.013 | 0.5 |
Schistosoma mansoni | subfamily S9B unassigned peptidase (S09 family) | 0.0209 | 0.1221 | 0.1105 |
Schistosoma mansoni | serine/threonine protein kinase | 0.1327 | 1 | 1 |
Echinococcus multilocularis | raf serine:threonine protein kinase | 0.1327 | 1 | 1 |
Mycobacterium tuberculosis | 3-oxoacyl-[acyl-carrier-protein] synthase III FabH (beta-ketoacyl-ACP synthase III) (KAS III) | 0.0383 | 0.2587 | 0.5 |
Leishmania major | dipeptidyl-peptidase 8-like serine peptidase, putative,serine peptidase, Clan SC, Family S9B | 0.007 | 0.013 | 0.5 |
Brugia malayi | prolyl oligopeptidase family protein | 0.0209 | 0.1221 | 0.1267 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.0383 | 0.2587 | 0.5 |
Plasmodium falciparum | beta-ketoacyl-ACP synthase III | 0.0383 | 0.2587 | 0.5 |
Mycobacterium ulcerans | beta-ketoacyl synthase-like protein | 0.0383 | 0.2587 | 0.5 |
Trypanosoma brucei | serine peptidase, Clan SC, Family S9B | 0.007 | 0.013 | 0.5 |
Brugia malayi | Raf kinase | 0.1281 | 0.9637 | 1 |
Loa Loa (eye worm) | raf kinase | 0.132 | 0.9949 | 1 |
Brugia malayi | prolyl oligopeptidase family protein | 0.007 | 0.013 | 0.0135 |
Chlamydia trachomatis | oxoacyl-ACP synthase III | 0.0383 | 0.2587 | 0.5 |
Trypanosoma cruzi | serine peptidase, Clan SC, Family S9B | 0.007 | 0.013 | 0.5 |
Trypanosoma cruzi | dipeptidyl-peptidase 8-like serine peptidase | 0.007 | 0.013 | 0.5 |
Plasmodium vivax | beta-ketoacyl-acyl carrier protein synthase III precursor, putative | 0.0383 | 0.2587 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | 3-oxoacyl-ACP synthase | 0.0383 | 0.2587 | 0.5 |
Loa Loa (eye worm) | prolyl oligopeptidase | 0.0209 | 0.1221 | 0.1227 |
Echinococcus multilocularis | dipeptidyl aminopeptidaseprotein | 0.0209 | 0.1221 | 0.1105 |
Loa Loa (eye worm) | TKL/RAF/RAF protein kinase | 0.0752 | 0.5487 | 0.5515 |
Onchocerca volvulus | Dipeptidyl peptidase family member 1 homolog | 0.0209 | 0.1221 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 5.6 nM | Inhibition of human DPP4 | ChEMBL. | 17293118 |
IC50 (binding) | = 5.6 nM | Inhibition of human DPP4 | ChEMBL. | 17293118 |
Inhibition (functional) | 0 | Ex vivo inhibition of DPP4 in cynomolgus monkey at 1 mg/kg, po after 12 hrs | ChEMBL. | 17293118 |
Inhibition (functional) | = 16 % | Ex vivo inhibition of DPP4 in beagle dog at 1 mg/kg, po after 12 hrs | ChEMBL. | 17293118 |
Inhibition (binding) | = 71 % | Ex vivo inhibition of DPP4 in Sprague-Dawley rats plasma at 1 mg/kg, po after 12 hrs | ChEMBL. | 17293118 |
Inhibition (binding) | = 71 % | Ex vivo inhibition of DPP4 in Sprague-Dawley rats plasma at 1 mg/kg, po after 12 hrs | ChEMBL. | 17293118 |
Inhibition (binding) | = 77 % | Ex vivo inhibition of DPP4 in Sprague-Dawley rats plasma at 1 mg/kg, po after 10 hrs | ChEMBL. | 17293118 |
Inhibition (binding) | = 77 % | Ex vivo inhibition of DPP4 in Sprague-Dawley rats plasma at 1 mg/kg, po after 10 hrs | ChEMBL. | 17293118 |
Inhibition (binding) | = 86 % | Ex vivo inhibition of DPP4 in Sprague-Dawley rat plasma at 1 mg/kg, po after 6 hrs | ChEMBL. | 17293118 |
Inhibition (binding) | = 86 % | Ex vivo inhibition of DPP4 in Sprague-Dawley rat plasma at 1 mg/kg, po after 6 hrs | ChEMBL. | 17293118 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.